Aduro Biotech Announces Management Promotions
April 20 2017 - 4:05PM
Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with
three distinct immunotherapy technologies, today announced the
promotion of Michele DeVries to vice president, regulatory affairs
and Celeste Ferber to vice president, associate general counsel.
“I am pleased to announce the promotion of Michele DeVries and
Celeste Ferber, who have each demonstrated expertise in their
respective areas that is critical to the continued growth and
success of our company,” said Stephen T. Isaacs, chairman,
president and CEO of Aduro Biotech. “Both Michele and Celeste have
played an integral role in our ongoing clinical and corporate
development efforts, and we are pleased to add them to our
leadership team. As we advance our programs into late stage
development and set our sights on commercialization, Michele’s
proven track record of effectively liaising with regulatory
agencies and corporate partners, and Celeste’s extensive expertise
in counseling public companies and astute business acumen, will
continue to be of great value to Aduro.”
Michele DeVries, vice president, regulatory affairs, has been
with Aduro since April 2013 and is responsible for all aspects of
regulatory strategy, implementation and oversight of Aduro’s
proprietary, partnered and licensed programs, both in the U.S. and
internationally. Prior to Aduro, Ms. DeVries served as director of
regulatory affairs for Intarcia Therapeutics where she managed key
regulatory aspects of their drug delivery system, was the primary
contact for regulatory authorities and responsible for all aspects
of routine and specialized regulatory submissions including
preparation for launch of four global Phase 3 studies. Before
Intarcia, she held escalating regulatory affairs positions at
VaxGen, InterMune and Tularik. She received her B.S. in
Chemical Engineering from the University of Minnesota.
Celeste Ferber, vice president, associate general counsel, has
been with Aduro since February 2016. Prior to Aduro, she was with
Shearman & Sterling LLP, where she served as counsel in the
capital markets group. Ms. Ferber has over 15 years of
experience advising public and private companies on corporate and
finance matters, including securities offerings, mergers,
acquisitions and strategic transactions, corporate governance and
securities law compliance. Before Shearman & Sterling, Ms.
Ferber was counsel at Morrison & Foerster LLP working in their
Palo Alto, Hong Kong and San Diego offices. Ms. Ferber received her
J.D. from the University of California, Hastings College of Law and
her B.A. in Economics from Bucknell University. She is the author
of numerous publications regarding legal matters.
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
mesothelioma, ovarian, lung and prostate cancers. Additionally, a
personalized form of LADD, or pLADD, is being developed utilizing
tumor neoantigens that are specific to an individual patient’s
tumor. Aduro's STING Pathway Activator platform is designed to
activate the STING receptor in immune cells, resulting in a potent
tumor-specific immune response. ADU-S100 is the first STING Pathway
Activator compound to enter the clinic and is currently being
evaluated in a Phase 1 study in patients with cutaneously
accessible metastatic solid tumors or lymphomas. Aduro’s B-select
monoclonal antibody platform includes a number of immune modulating
assets in research and preclinical development. Aduro is
collaborating with leading global pharmaceutical companies to
expand its products and technology platforms. For more information,
please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, our technology platforms, plans,
and the potential for eventual regulatory approval of our product
candidates. In some cases, you can identify these statements by
forward-looking words such as “may,” “will,” “continue,”
“anticipate,” “intend,” “could,” “project,” “seek”, “expect” or the
negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results and events to differ materially from those anticipated,
including, but not limited to, our history of net operating losses
and uncertainty regarding our ability to achieve profitability, our
ability to develop and commercialize our product candidates, our
ability to use and expand our technology platforms to build a
pipeline of product candidates, our ability to obtain and maintain
regulatory approval of our product candidates, our ability to
operate in a competitive industry and compete successfully against
competitors that have greater resources than we do, our reliance on
third parties, and our ability to obtain and adequately protect
intellectual property rights for our product candidates. We
discuss many of these risks in greater detail under the heading
“Risk Factors” contained in our annual report on Form 10-K for the
year ended December 31, 2016, which is on file with the Securities
and Exchange Commission. Any forward-looking statements that we
make in this press release speak only as of the date of this press
release. We assume no obligation to update our forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
Media Contact:
Susan Lehner
510 809 2137
press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024